期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 121, 期 3, 页码 1088-1101出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI44960
关键词
-
资金
- NIH [P01 AI057127-01A1, R37 AI044628, R01-AI28900, AI047033, 1UL1RR029893]
- CHAVI [U01 AI 067854]
- Bill and Melinda Gates Foundation [RFP-GH-HTR-05-02]
- Rockefeller University CCTA
- National Center for Research Resources (NCRR), NIH [UL1 RR024143-01]
- NIH Roadmap for Medical Research
- General Clinical Research Centers [M01 NIH RR00096]
- Center for AIDS Research [P30 AI027742]
- NYULMC
Plasmacytoid DCs (pDCs) are innate immune cells that are specialized to produce IFN-alpha and to activate adaptive immune responses. Although IFN-alpha inhibits HIV-1 replication in vitro, the production of IFN-alpha by HIV-activated pDCs in vivo may contribute more to HIV pathogenesis than to protection. We have now shown that HIV-stimulated human pDCs allow for persistent IFN-alpha production upon repeated stimulation, express low levels of maturation molecules, and stimulate weak T cell responses. Persistent IFN-alpha production by HIV-stimulated pDCs correlated with increased levels of IRF7 and was dependent upon the autocrine IFN-alpha/beta receptor feedback loop. Because it has been shown that early endosomal trafficking of TLR9 agonists causes strong activation of the IFN-alpha pathway but weak activation of the NF-kappa B pathway, we sought to investigate whether early endosomal trafficking of HIV, a TLR7 agonist, leads to the IFN-alpha-producing phenotype we observed. We demonstrated that HIV preferentially traffics to the early endosome in human pDCs and therefore skews pDCs toward a partially matured, persistently IFN-alpha-secreting phenotype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据